sintilimab
innovent biologics,eli lilly
['sclc', 'nsclc', 'sintilimab', 'orient-11']
 perhaps relevant that when fda rejected sintilimab for advanced nsclc, one of the reasons was that the control arm of orient-11 trial did not reflect standard of care in the usa. it didn't matter that the control arm was soc in other countries. (slide 13 
Assistant Professor, Pharmacology and Computational Medicine at @UNC
Measuring and modeling combination cancer therapy